Published in
Elsevier, Journal of The American Academy of Dermatology, 6(83), p. AB16, 2020
DOI: 10.1016/j.jaad.2020.06.152
Links
Tools
14020 Durability of responses with bimekizumab, a selective dual inhibitor of interleukin-17A and -17F, in moderate to severe chronic plaque psoriasis in a 60-week randomized, double-blinded, phase 2b study (BE ABLE 2)
Journal article published in 2020 by
Andrew Blauvelt,
Joseph F. Merola,
Kim Alexander Papp,
Melinda Gooderham,
Alice B. Gottlieb,
Christopher Cioffi,
Luke Peterson,
Nancy Cross,
Christopher Griffiths,
Diamant Thaci
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 